These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30963795)

  • 1. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
    Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
    Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
    Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
    Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
    FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.
    Sciarrillo R; Terrana F; Comandatore A; Supadmanaba IGP; Wang B; Hassouni BE; Mantini G; Jansen G; Avan A; Carbone D; Diana P; Peters GJ; Morelli L; Cloos J; Assaraf YG; Giovannetti E
    Int J Biol Sci; 2024; 20(8):3173-3184. PubMed ID: 38904016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin.
    Vanzyl EJ; Rick KRC; Blackmore AB; MacFarlane EM; McKay BC
    PLoS One; 2018; 13(1):e0191178. PubMed ID: 29338026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
    Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
    RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
    López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
    Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
    Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
    Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
    Kim Guisbert KS; Mossiah I; Guisbert E
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of splicing factor poly(rC)-binding protein 1 elicits cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells.
    Chen Y; Dou Z; Chen X; Zhao D; Che T; Su W; Qu T; Zhang T; Xu C; Lei H; Li Q; Zhang H; Di C
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3475-3484. PubMed ID: 35896897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
    Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
    Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diallyl disulfide enhances carbon ion beams-induced apoptotic cell death in cervical cancer cells through regulating Tap73 /ΔNp73.
    Di C; Sun C; Li H; Si J; Zhang H; Han L; Zhao Q; Liu Y; Liu B; Miao G; Gan L; Liu Y
    Cell Cycle; 2015; 14(23):3725-33. PubMed ID: 26505313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.
    Gao Y; Trivedi S; Ferris RL; Koide K
    Sci Rep; 2014 Aug; 4():6098. PubMed ID: 25139387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.